Skip to main content
David Raben, MD, Radiation Oncology, Aurora, CO, UCHealth Memorial Hospital

DavidRabenMD

Radiation Oncology • Aurora, CO

Head & Neck, Urologic Cancer

Professor of Radiation Oncology University of Colorado Cancer Center

Join to view full profile

Dr. Raben is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Raben's full profile

Already have an account?

Summary

  • Dr. David Raben is a board certified radiation oncologist and holds the rank of Professor at the University of Colorado. He is listed as a "Top Doctor" by U.S. News and World Report. He received his undergraduate degree at Duke University (1981-1985) and his medical degree from Wake Forest University Health Sciences Center (1985-1990). Residency training in radiation oncology was conducted at the John Hopkins Hospital (1991-1994). He took his initial faculty position at the University of Alabama at Birmingham from 1994-1998 heading the GI tumor working group and receiving an American Cancer Society translational oncology grant to study brain tumors. Having joined the faculty at the University of Colorado in 1998, an NCI-designated Comprehensive Cancer Center he is a member of the Lung, Head & Neck Cancers Program of the University of Colorado Cancer Center. Dr Raben has extensive expertise in aerodigestive track malignancies with specific focus in head and neck cancer (HNC), Lung, Prostate and Bladder cancer and has provided contributions to the University of Colorado Cancer Center through pre-clinical and clinical investigations. Dr. Raben is an active member of the School of Medicine Admissions committee, having served over the past 15 years and currently teaches medical students in the Problem Based Learning Program.
    Having developed interests and expertise over the past 20 years in translational radiation oncology with a focus on delivery of precision drugs, Dr. Raben has explored molecular biomarkers and targets that will enhance the effects of radiation therapy in HNC. Nationally, Dr. Raben is an active participant in the NRG head and neck cancer steering committee and translational committee focusing on national, NCI approved clinical trials devoted to HNC. He serves on the SWOG Genitourinary steering comm. as well. He has over 140 peer reviewed publications and is a member of AACR, ASCO and ASTRO.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Radiation Oncology, 1991 - 1994
  • University of Hawaii
    University of HawaiiInternship, Transitional Year, 1990 - 1991
  • Wake Forest School of Medicine of Wake Forest Baptist Medical Center
    Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1990

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 1998 - 2025
  • AL State Medical License
    AL State Medical License Active through 1999
  • MD State Medical License
    MD State Medical License 1991 - 1993
  • HI State Medical License
    HI State Medical License 1990 - 1992
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Selected for the American Society of Clinical Oncology Ambassador Program for Multidisciplinary Cancer Management Courses ASCO
  • Top Doctor U.S. News and Report, 2016
  • Selected to participate in Univ. of Colorado CCTSI Leadership in Team Science Program (LITeS) CCTSI, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients with Oral Cavity Cancer  
    Ding Ding, Whitney Sumner, David Raben, Mohammad Hararah, Jessica McDermott, Sana D Karam, Julie Goddard, Hilary Somerset, JAMA
  • Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer  
    Hilary Somerset, Antonio Jimeno, David Raben, Sana D Karam, Dara L Aisner, Madeleine Kane, Carrie Marshall, Daniel W Bowles, Clinical Cancer Research
  • The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer  
    David Raben, MD, Clinical Cancer Research
  • Join now to see all

Press Mentions

  • China Regulator Accepts Akeso, Sino Biopharm Application for Cancer Drug
    China Regulator Accepts Akeso, Sino Biopharm Application for Cancer DrugAugust 5th, 2021
  • Cancer Fight Shows Way for U.S., China to Cool off, Collaborate: Kevin Rudd
    Cancer Fight Shows Way for U.S., China to Cool off, Collaborate: Kevin RuddAugust 16th, 2020
  • NANOBIOTIX Announces Positive Phase II/III Topline Data in Soft Tissue Sarcoma with NBTXR3
    NANOBIOTIX Announces Positive Phase II/III Topline Data in Soft Tissue Sarcoma with NBTXR3June 21st, 2018
  • Join now to see all

Committees

  • Member, SWOG GU Steering Comm 2013 - 2017
  • Member, NRG Head and Neck Steering comm 2007 - 2017

Professional Memberships

Hospital Affiliations

External Links

Dr. David Raben, Dr. David Raben, MD, Dr. D Raben